Objectives: To study the long-term results of the treatment of patients with vaginal cancer and to examine whether there are any differences in diagnostic and survival rates between urban and rural patients. Methods:The data of 70 patients with primary vaginal cancer treated at NN Alexandrov National Cancer Centre of Belarus from 2000 to 2019 were included. The median age was 64 years (range = 56-75). Morphology in 91.4% (64/70) of the cases was squamous cell cancer, in 7.1% (5/70) it was adenocarcinoma and in 1.4% (1/70) it was adenosquamous carcinoma. In total, there were 31 patients from urban and 39 from rural areas. The groups were comparable in age (61 versus 67, p = 0.104), morphology (p = 0.188) and distribution of stages: stage I in 7 and 10 patients (22.6% and 25.6%, respectively; p = 0.999), stage II in 14 and 16 patients (45.1% and 41.0%, respectively; p = 0.810), stage III in 6 and 6 patients (19.4% and 15.4%, respectively; p = 0.754) and stage IV in 4 and 7 patients (12.9% and 18.0%, respectively; p = 0.744). ResultsThe median follow-up time was 33 months (range = 1-220). A total of 42 women died: 28 from progression of vaginal cancer and 14 from other diseases. Overall survival (OS) was 31.9 ± 6.8%, median survival was 41 months (95% CI = 0.0-105.3). Diseasespecific survival (DSS) for the entire group was 54.5 ± 6.8%; median was not reached. The overall survival rate of urban women was 44.8 ± 10.6% and for rural it was 22.5 ± 8.2% (p = 0.142); DSS was 57.6 ± 10.5% and 53.0 ± 8.4% (p = 0.448), respectively. Conclusion DSS rate was 54.0 ± 6.8% and the OS rate did not exceed 31.9 ± 6.8%. Rural residence was not associated with late stage at diagnosis or receipt of treatment.
2022-RA-226-ESGO Figure 1 Proportion of needs for 15 items of the supportive care needs survey short form Conclusion Women with newly diagnosed vulvar cancer request predominantly information about treatment, side-Abstracts
Methodology We are reporting three different cases with choriocarcinoma with different presentations whether postmenopausal presentation, isthmic lesions, and later presentation after hysterectomy with vaginal metastasis. Result(s)* All cases were managed surgically with reporting of their management in detail. Conclusion* The majority of choriocarcinoma cases are intrauterine and of gestational origin. postmenopausal and cervical choriocarcinoma are rare presentations of this pathology. It is important to include cervical choriocarcinoma in the differential diagnosis of cervical lesions during the reproductive age despite the extremely low incidence as an ectopic entity. Choriocarcinoma is completely curable by chemotherapy even in the presence of metastasis. If massive life-threatening vaginal bleeding occurs, surgery is needed. We should consider vaginal metastasis in any vaginal mass after hysterectomy for a suspected tumor as a vesicular mole or endometrial cancer.
Цель исследования: проанализировать результаты лечения рецидивного неоперабельного рака слизистой оболочки полости рта и глотки с применением цетуксимаба. Материалы и методы. Проспективное исследование эффективности лечения рецидивного неоперабельного рака слизистой оболочки полости рта и глотки с применением цетуксимаба 20 пациентов в возрасте от 32 до 70 лет, из них мужчин - 13, женщин - 7. Девяти (45,0%) пациентам проводилась монотерапия цетуксимабом, 11 (55,0%) пациентам - с добавлением цетуксимаба к схемам полихимиотерапии, включающим платиносодержащие препараты: TPeX (4 пациента), TPF (3 пациента), PF (1 пациент), а также в комбинации с карбоплатином (3 пациента). Эффективность лечения определялась по критериям оценки ответа солидных опухолей RECIST 1.1 с учетом рекомендаций по оценке эффективности иммунотерапии IrRECIST. Результаты и обсуждение. Длительность наблюдения пациентов составила от 0,6 до 16,3 мес. Частичная ремиссия наблюдалась у 3 (15%) пациентов, стабилизация опухолевого процесса - у 11 (55%) пациентов. Прогрессирование заболевания отмечено у 6 (30%) пациентов. Общая выживаемость пациентов с рецидивным плоскоклеточным раком слизистой оболочки полости рта и ротоглотки, получавших терапию с цетуксимабом, составила 22,9±12,5%, медиана выживаемости - 8,7 (95% ДИ 7,1-10,3) месяца. Однолетняя выживаемость составила 43,0±12,0%. Не установлено статистически достоверной взаимосвязи между общей выживаемостью и режимом иммунотерапии цетуксимабом (монотерапия/комбинация с платиносодержащими препаратами (r=0,33; p>0,05). Заключение. Полученные результаты свидетельствуют о возможности достижения локорегионарного контроля в 70% случаев, а медиана общей выживаемости пациентов, получавших терапию с цетуксимабом, сопоставима с данными исследования EXTREME, что позволяет считать приведенные результаты удовлетворительными, принимая во внимание сложность лечения данной категории пациентов. Purpose. To analyze the results of treatment of recurrent inoperable cancer of the oral cavity and oropharynx using cetuximab. Materials and methods. There was conducted a prospective study of the effectiveness of treatment of the recurrent inoperable oral and oropharyngeal cancer using cetuximab in 20 patients aged from 32 to 70 years (13 men, 7 women). 9 (45.0%) patients received cetuximab monotherapy, 11 (55.0%) patients - with the addition of cetuximab to polychemotherapy regimens that include platinum- containing drugs: TPeX (4 patients), TPF (3 patients), PF (1 patient), as well as in combination with carboplatin (3 patients). The effectiveness of treatment was determined according to the RECIST 1.1 criteria for evaluating the response of solid tumors, taking into account the recommendations for evaluating the effectiveness of IrRECIST immunotherapy. Results and discussion. The duration of the patients’ follow-up ranged from 0.6 to 16.3 months. Partial remission was observed in 3 (15%) patients, stabilization of the tumor process - in 11 (55%) patients. Disease progression was observed in 6 (30%) patients. Overall survival of patients with recurrent squamous cell carcinoma of the oral and oropharyngeal cancer treated with cetuximab was 22.9±12.5%, median survival was 8.7 (95% CI 7.1-10.3) months. The one-year survival rate was 43.0±12.0%. There was no statistically significant relationship between overall survival and the cetuximab immunotherapy regimen (monotherapy/combination with platinum-containing drugs (r=0.33; p>0.05). Conclusion. The obtained results indicate the possibility of achieving locoregional control in 70% of cases, and the median overall survival of patients receiving therapy with cetuximab is comparable to the data of the EXTREME study, which allows us to consider these results as satisfactory, taking into account the complexity of treatment of this category of patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.